Clinical/contract research organisations (CROs) in particular are among the strongest growth sectors of the pharmaceutical industry, with many firms across the sector experiencing double- digit annual growth. This growth is driven by the trend for increased outsourcing by pharmaceutical and biotechnology companies looking to shift fixed to variable costs and access specialist capabilities not found in-house, and an overall increase in biopharmaceutical R&D spending. CROs have also become one of the most active sectors for M&A, with larger players consolidating to achieve critical mass, as well as completing bolt-on acquisitions to offer a more comprehensive service offering.
Our team has a strong track-record in successful CRO transactions.
Find out more View All
"The team provided fantastic support throughout the sale process and enabled the company to achieve a much better outcome than was originally thought possible. The founders of Bridgehead would have no hesitation in selecting Results for future transactions and would recommend them very highly to others."